

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai HeartCare Medical Technology  
Corporation Limited**

**上海心瑋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6609)**

**ANNOUNCEMENT IN RELATION TO  
DEALINGS IN SECURITIES OF A DIRECTOR  
DURING THE BLACK-OUT PERIOD**

This announcement is made by Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”) pursuant to paragraph D.15 of Appendix C3 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors (“**Directors**”) of the Company has been notified by Ms. Zhang Kun (“**Ms. Zhang**”), an executive Director, that Ningbo Tongchuangsuwei Investment Partnership (LP)\* (寧波同創速維投資合夥企業(有限合夥), “**Tongchuangsuwei**”), a limited partnership controlled by Mr. Chai Yanpeng (Ms. Zhang’s spouse) as its general partner, and Ms. Zhang is deemed interested in the same amount of shares in which Tongchuangsuwei is interested, entered into on-market transactions disposing of a total of 99,650 H shares (“**H Share(s)**”) of the Company at consideration between HK\$52.0 to HK\$65.2 per H Share (the “**Transfers**”) during the period between July 30, 2025 to August 22, 2025, without first having notified the Company prior to the Transfers in accordance with the requirements of paragraph B.8 of Appendix C3 to the Listing Rules. As a result of the Transfers, the shareholding interest that Ms. Zhang is regarded to be interested in has been reduced from approximately 4.42% to 4.11% of the total issued H Shares of the Company as at August 22, 2025. The Company was also informed that Tongchuangsuwei disposed of 170,950 H Shares between July 2, 2025 and July 29, 2025 for a consideration of between HK\$35.0 and HK\$55.35 per H Share, as well as another 86,200 H Shares between September 1, 2025 to September 15, 2025 for a consideration of between HK\$58.0 and HK\$67.05 per H Share without first having notified the Company in accordance with the requirements of paragraph B.8 of Appendix C3 to the

Listing Rules. To the best of the Company's knowledge, the H Shares that Ms. Zhang is regarded to be interested in further reduced to approximately 3.83% of the total issued H Share of the Company as at the date of this announcement.

Pursuant to paragraph A.3 of Appendix C3 to the Listing Rules, the Directors are prohibited from dealing in any securities of the Company on any day on which its financial results are published and during the period of 30 days immediately preceding the publication date of the interim results of the Company for the six months ended June 30, 2025 (the **"Interim Results"**), as well as any period of delay in the publication of the Interim Results announcement (the **"Black-out Period"**). As disclosed in the announcement of the Company dated August 19, 2025, the meeting of the Board for the publication of the Interim Results is scheduled on August 29, 2025 and the Transfers therefore fell within the Black-out Period and constituted a dealing of Shares by Tongchuangsuwei, resulting in a non-compliance incident of paragraphs A.3 and B.8 of Appendix C3 to the Listing Rules (the **"Non-compliance Incident"**).

Ms. Zhang reported the Non-compliance Incident to the Company and confirmed that the non-compliance was an inadvertent oversight by the managing team of Tongchuangsuwei and as Ms. Zhang was in a passive position in relation to the Transfers, she did not intend to commit such breach. Ms. Zhang further confirmed that she will apply closer scrutiny towards Appendix C3 of the Listing Rules.

Upon becoming aware of the Non-compliance Incident, the Company has immediately reminded the Directors and senior management again of the requirements of the Appendix C3 to the Listing Rules and the importance of strict compliance with such provision by the Directors and their close associates. In order to ensure ongoing compliance with the Appendix C3 to the Listing Rules and prevent similar incidents in the future, the Company will provide regular training to the Directors, senior management and staff of the Company so as to keep them abreast of the relevant requirements. The Company will also circulate Appendix C3 to the Listing Rules and remind the Directors to compliance with its requirements in greater frequency to ensure compliance with and enhance their awareness of good corporate governance practices.

By order of the Board  
**Shanghai HeartCare Medical Technology Corporation Limited**  
**WANG Guohui**  
*Chairman of the Board*

Hong Kong, September 18, 2025

*As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Ding Kui, Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.*

\* *For identification purposes only*